Effect of Cabergoline Added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese Type 2 Diabetic Patients

Hayder Ch. Assad

Authors

Hayder Ch. Assad

Keywords:

cabergoline, glycemic control, insulin resistance, beta-cell function, obesity, type 2 diabetes

Abstract

The aim of this study is to examine the effect of cabergoline added to metformin on glycemic control, insulin resistance and B-cell function in obese type 2 diabetic patients. Forty obese patients with newly diagnosed type2 diabetes were enrolled in this study and randomized by 1:1 ratio into group (I) receives metformin and group (II) receives metformin plus cabergoline for 12 week. We evaluated fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) every 4 week while body weight, glycosylated hemoglobin, fasting plasma insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and B-cell function (HOMA-B) at the baseline and after 12 week.

Downloads

How to Cite

Effect of Cabergoline Added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese Type 2 Diabetic Patients. (2014). Global Journal of Medical Research, 14(38), 25-31. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

Yi Lin, Zhongjie Sun (2010) Current views on type 2 diabetes.J of Endocrinol. 204(1), 1-11. https://doi.org/10.1677/joe-09-0260

A. Astrup, N. Finer (2000) Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus?. 1(2), 57-9.

Lalita Khaodhiar, Sue Cummings, Caroline Apovian (2009) Treating diabetes and prediabetes by focusing on obesity management. 9(5), 348-354. https://doi.org/10.1007/s11892-009-0055-0

Ralph DeFronzo (2009) From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. 58(4), 773-795. https://doi.org/10.2337/db09-9028

Pijl H (2003) Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome?. 480, 125-131.

Tschoner A, Engl J, Laimer M (2007) Metabolic side effects of antipsychotic medication. 61, 1356-1370.

Wang GJ, Volkow ND, Thanos PK (2009) Brain Dopamine Pathways and Obesity. 3(1), 8-18.

Uberto Pagotto (2009) Where Does Insulin Resistance Start?. 32(suppl_2), S174-S177. https://doi.org/10.2337/dc09-s305

Sudarshana Purkayastha, Dongsheng Cai (2013) Neuroinflammatory basis of metabolic syndrome. 2(4), 356-363. https://doi.org/10.1016/j.molmet.2013.09.005

Scranton RE, Ezrokhi M, Gaziano JM (2008) Quick Release Bromocriptine (Cycloset™) Improves Glycemic Control in Patients with Diabetes Failing Metformin/Sulfonylurea Combination Therapy.

L. Brunton, L. Parker, D. Blumenthal, &. Goodman, Gilman (2008) Manual of pharmacology and therapeutics. 1, 973-974.

Gibson CD, Karmally W, McMahon DJ (2012) Randomized Pilot Study of Cabergoline, a Dopamine Receptor Agonist: Effects on Body Weight and Glucose Tolerance in Obese Adults Diabetes Obes Metab.2012. 14(4), 335-340. https://doi.org/10.1111/j.1463-1326.2011.01534.x

Usluogullari Inancli SS, Ustu (2013) Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.Endocrine. 44(1), 193-199. https://doi.org/10.1007/s12020-012-9857-y

Muniyappa R, Lee S, Chen H (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. 294, E15-E26.

S. Taghavi, S. Fatemi, H. Rokni (2012) Cabergoline Effect on Blood Sugar in Type 2 Diabetic Patients with Oral Agent Failure. 67(4), 390-392.

Kok P, Roelfsema F, Frolich M (2006) Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.

N. Merican, N. Sukor, A. Razali (2013) The Effects of Short Term Cabergoline Therapy on Disease Activity and Metabolic Parameters in Acromegaly .Journal of Endocrinology and Metabolism. 3(1), 48-56.

Amato Ciresi A (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. 79, 845-852.

Krysiak Rand Okopien, B. (2014) Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels. (8).

Cincotta AH, Meier AH, Cincotta MJ (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. 8, 1683-1707.

Ghosh A, Sengupta N, Sahana P (2014) Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial. 46(1), 24. https://doi.org/10.4103/0253-7613.125160

Keshavan Bina, Anthony Cincotta (2000) Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice. 71(1), 68-78. https://doi.org/10.1159/000054522

Ralph DeFronzo (2011) Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes. 34(4), 789-794. https://doi.org/10.2337/dc11-0064

Liang Y, Lubkin M, Sheng H (1998) Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. 1405, 1-13.

R. Turner, A. Rudenski, D. Matthews (1990) Application of structural model of glucoseinsulin relations to assess beta-cell function and insulin sensitivity. 24(Suppl), 66-71.

Tara Wallace, Jonathan Levy, David Matthews (2004) Use and Abuse of HOMA Modeling. 27(6), 1487-1495. https://doi.org/10.2337/diacare.27.6.1487

Berinder K, Nystrom T, Hoybye C (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. 14(3), 199-207. https://doi.org/10.1007/s11102-010-0277-9

Dos CM, Barbosa FR, Lima GA (2011) BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists. 19(4), 800-805. https://doi.org/10.1038/oby.2010.150

Ezrokhi M, Luo L, Cincotta A (2012) Weighted Effects of Bromocriptine Treatment on Glucose Homeostasis during Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer. S2(01).

Anan F, Takahashi N, Nakagawa M (2005) Metabolism. 54(4), 552-558.

Corkey BE (2012) Hyperinsulinemia: Cause or Consequence?. 61(1), 4-13.

Alessandro Ustione, David Piston, Paul Harris (2013) Minireview: Dopaminergic Regulation of Insulin Secretion from the Pancreatic Islet. 27(8), 1198-1207. https://doi.org/10.1210/me.2013-1083

M. Sowell, N. Mukhopadhyay, P. Cavazzoni (2002) Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo. 87(6), 2918-2923. https://doi.org/10.1210/jc.87.6.2918

Garcia-Tornado I, Ornstein AM, Chamson-Reig A (2010) Disruption of TEJ dopamine D2 receptor impairs insulin secretion and glucose intolerance. 151(4), 1441-1450.

Rebecca Brown, Kristina Rother (2008) Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. 9(3pt2), 14-22. https://doi.org/10.1111/j.1399-5448.2007.00272.x

Thomas Jetton, Yin Liang, Anthony Cincotta (2001) Systemic treatment with sympatholytic dopamine agonists improves aberrant [beta ]-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice. 50(11), 1377-1384. https://doi.org/10.1053/meta.2001.26741

Pivonello R, De C, Cappabianca P (2009) The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery. 94(1), 223-230. https://doi.org/10.1210/jc.2008-1533

Galdiero M, Auriemma R, Vitale P (2014) Effect of chronic treatment with cabergoline and testosterone replacement on metabolic parameters in male patients with prolactinomas and hypogonadism. 35, 865. https://doi.org/10.1530/endoabs.35.p865

Ki-Chul Sung, Gerald Reaven, Sun Kim (2010) Utility of Homeostasis Model Assessment of β-Cell Function in Predicting Diabetes in 12,924 Healthy Koreans. 33(1), 200-202. https://doi.org/10.2337/dc09-1070